<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Han S</submitter><funding>Canadian Institutes of Health Research</funding><funding>CIHR</funding><pagination>437-452</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9662906</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>10(4)</volume><pubmed_abstract>Regulatory T cells (Treg) are an integral component of the adaptive immune system that negatively affect antitumor immunity. Here, we investigated the role of the E3 ubiquitin ligase casitas B-lineage lymphoma-b (Cbl-b) in establishing CD8+ T-cell resistance to Treg-mediated suppression to enhance antitumor immunity. Transcriptomic analyses suggested that Cbl-b regulates pathways associated with cytokine signaling and cellular proliferation. We showed that the hypersecretion of IFNγ by Cbl-b-deficient CD8+ T cells selectively attenuated CD8+ T-cell suppression by Tregs. Although IFNγ production by Cbl-b-deficient T cells contributed to phenotypic alterations in Tregs, the cytokine did not attenuate the suppressive function of Tregs. Instead, IFNγ had a profound effect on CD8+ T cells by directly upregulating interferon-stimulated genes and modulating T-cell activation. In murine models of adoptive T-cell therapy, Cbl-b-deficient T cells elicited superior antitumor immune response. Furthermore, Cbl-b-deficient CD8+ T cells were less susceptible to suppression by Tregs in the tumor through the effects of IFNγ. Collectively, this study demonstrates that the hypersecretion of IFNγ serves as a key mechanism by which Cbl-b-deficient CD8+ T cells are rendered resistant to Tregs. See related Spotlight by Wolf and Baier, p. 370.</pubmed_abstract><journal>Cancer immunology research</journal><pubmed_title>Overproduction of IFNγ by Cbl-b-Deficient CD8+ T Cells Provides Resistance against Regulatory T Cells and Induces Potent Antitumor Immunity.</pubmed_title><pmcid>PMC9662906</pmcid><funding_grant_id>CIHR-FDN 143220</funding_grant_id><pubmed_authors>Garcia-Batres CR</pubmed_authors><pubmed_authors>Liu ZQ</pubmed_authors><pubmed_authors>Paul MS</pubmed_authors><pubmed_authors>Elford AR</pubmed_authors><pubmed_authors>Grimshaw N</pubmed_authors><pubmed_authors>Gold MJ</pubmed_authors><pubmed_authors>Ohashi PS</pubmed_authors><pubmed_authors>Han S</pubmed_authors><pubmed_authors>Chung DC</pubmed_authors><pubmed_authors>Sayad A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Overproduction of IFNγ by Cbl-b-Deficient CD8+ T Cells Provides Resistance against Regulatory T Cells and Induces Potent Antitumor Immunity.</name><description>Regulatory T cells (Treg) are an integral component of the adaptive immune system that negatively affect antitumor immunity. Here, we investigated the role of the E3 ubiquitin ligase casitas B-lineage lymphoma-b (Cbl-b) in establishing CD8+ T-cell resistance to Treg-mediated suppression to enhance antitumor immunity. Transcriptomic analyses suggested that Cbl-b regulates pathways associated with cytokine signaling and cellular proliferation. We showed that the hypersecretion of IFNγ by Cbl-b-deficient CD8+ T cells selectively attenuated CD8+ T-cell suppression by Tregs. Although IFNγ production by Cbl-b-deficient T cells contributed to phenotypic alterations in Tregs, the cytokine did not attenuate the suppressive function of Tregs. Instead, IFNγ had a profound effect on CD8+ T cells by directly upregulating interferon-stimulated genes and modulating T-cell activation. In murine models of adoptive T-cell therapy, Cbl-b-deficient T cells elicited superior antitumor immune response. Furthermore, Cbl-b-deficient CD8+ T cells were less susceptible to suppression by Tregs in the tumor through the effects of IFNγ. Collectively, this study demonstrates that the hypersecretion of IFNγ serves as a key mechanism by which Cbl-b-deficient CD8+ T cells are rendered resistant to Tregs. See related Spotlight by Wolf and Baier, p. 370.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Apr</publication><modification>2026-05-29T03:04:30.073Z</modification><creation>2026-04-08T03:39:42.559Z</creation></dates><accession>S-EPMC9662906</accession><cross_references><pubmed>35181779</pubmed><doi>10.1158/2326-6066.CIR-20-0973</doi></cross_references></HashMap>